Health-related decisions require evidence people can understand and trust.

Understand how search and AI shape confidence in pharmaceutical information.

Patients, caregivers and professionals may use search to understand conditions, products, indications, safety, administration, availability, reputation and questions for a qualified healthcare professional.

Search Intelligence examines whether material information is accurate, appropriately framed, supported, consistent, accessible and responsibly owned.

Request a Pharmaceutical Diagnostic Conversation Explore AI Narrative Integrity

Publication note

Final sector wording, claims and scope require specialist Pharmaceutical, Regulatory, Medical and Legal approval.

See solutions by organisation and sector →

Decision environment

May involve:

Patients Caregivers Healthcare professionals Pharmacies Distributors Publishers Support organisations AI systems Regulated owned content

Not every search reflects purchase intent. It may be educational, clinical, safety-related, access-related or emotionally sensitive.

The first governance requirement is correct classification of

Audience Purpose Evidence Permitted claims Required review

Core information questions

What is this product or treatment?

What is it indicated for?

What should be discussed with a healthcare professional?

What evidence supports the information?

Is the source current?

Is AI accurate?

Are limitations or safety information missing?

Is the content for patients, caregivers or professionals?

Where is the authoritative source?

SI does not provide medical advice.

The evidence customers need to trust →

Exposures

Product-Information Integrity

Approved facts and consistency.

Indication and Audience Integrity

Appropriate content for the intended audience.

Source-of-Truth Governance

Ownership, versioning and approval.

AI Narrative Integrity

Omission, distortion or oversimplification.

Technical Integrity

Accessibility, indexability and presentation.

Reputation and Misinformation

Outdated or unsupported narratives.

Third-Party Representation

Publishers, pharmacies, distributors and other sources.

Evidence and Approval

Claims traceable to approved evidence.

Governing boundary

SI may identify

Inconsistency Omission Distortion Outdated sources Accessibility Source patterns Representation risk Ownership gaps

Search Governance may route to

Medical Regulatory Legal Pharmacovigilance Product Corporate Affairs Digital Information Governance

SI does not determine

Clinical suitability

Treatment

Safety conclusions

Regulatory approval

Medical advice

Exposure and decision effects

Information becomes available

↓

The person evaluates it

↓

An interpretation forms

↓

Confidence or concern changes

↓

A later health-related decision may occur

Distinguish

Observed exposure Observed or inferred encounter Inferred decision effect Validated evidence Unknowns

Possible assessment areas

Source mapping AI capture Omission and distortion Technical accessibility Third-party review Publisher and pharmacy representation Claim traceability Reputation and misinformation Ownership and approval Retention Correction and re-testing

Potential outputs

Pharmaceutical Search Exposure Map Source-of-Truth Register AI Narrative Integrity Record Omission and Distortion Register Approved Claims Traceability Map Technical Integrity Findings Third-Party Representation Review Search Risk Register Governance RACI Evidence and Approval Trail Executive Findings Session

Possible owners

Exposure	Possible owners
Product information	Medical, Regulatory, Product
Claims and evidence	Medical, Regulatory, Legal
Patient content	Medical, Regulatory, Communications
AI representation	Digital, Medical, Regulatory
Technical accessibility	Digital, IT, Development
Third-party representation	Corporate Affairs, Regulatory, Legal
Safety information	Pharmacovigilance, Medical, Regulatory
Source controls	Information Governance, Product, Regulatory
Misinformation	Corporate Affairs, Medical, Legal

Final ownership is organisation-specific.

Suitable conditions

AI representation is materially relevant

Product information is distributed widely

A launch or update is planned

Outdated content remains visible

Ownership is fragmented

Technical conditions affect approved information

Third-party representation requires review

A regulated source-of-truth model is needed

What it is not

Medical advice

Regulatory approval

Pharmacovigilance assessment

Clinical evidence review

Promotional approval

Replacement for Medical, Regulatory or Legal

Control over AI or search platforms

Begin with an approved scope and the right sector authorities in the room.

Request a Pharmaceutical Diagnostic Conversation Explore Search Evidence and Governance

Need a different scope?

Need a group-wide operating model? Explore Enterprise.

Need a focused growth scope? Explore Corporate.

Need a practical owner-led plan? Explore SME where relevant.